TP53 and myelodysplastic syndrome: Lindsley et al13 proposed an ontogeny-based classification for AML, which allows distinction of 3 genetic subgroups, a “TP53 subgroup,” an “AML with MDS mutations,” and a “de novo/pan-AML” subgroup which appeared to be relevant in de novo but also t-AML.